Ducentis Biotherapeutics Ltd.
09307415
Some Concerns
- 2 outstanding charges (-4)
Details
Compliance
Last accounts
31/12/2025
small
Next accounts due
30/09/2027
Confirmation statement
Last: 24/02/2026
Due 10/03/2027
Industry
Officers
Persons with Significant Control
Arcutis Biotherapeutics, Inc.
Suite 300, 3027 Townsgate Road, Ca 91361
Notified 09/09/2022
Former PSCs
Dr Philip Huxley
Ceased 09/09/2022
Dr David Mark Anthony Holbrook
Ceased 28/04/2021
Lifearc
Ceased 09/09/2022
Charges2 outstanding
SLR INVESTMENT CORP. AS AGENT (AS DEFINED IN THE INSTRUMENT)
SLR INVESTMENT CORP. (AS COLLATERAL AGENT FOR THE SECURED PARTIES)
CompanyRankvs 2009+ SIC 72110 peers33
Show leaderboard
How is this score calculated?
Net worth compared to all companies in the same SIC code with published accounts. Top quartile earns the full 25 points.
Workforce size relative to sector peers from the most recent accounts. A larger team generally signals commercial scale.
Current assets ÷ current liabilities. A ratio above 2× earns full marks; between 1–2× scores partially; below 0.5× scores minimal points.
One point per year of operation since incorporation, capped at 15. Older companies have a proven track record.
Full 15 points when both annual accounts and confirmation statement are filed on time. Points are deducted for each overdue filing.
Risk deductions
Outstanding charges: -10 pts
Maximum score is 100. Deductions apply for insolvency history, outstanding charges, going concern doubt, or disqualified officers.
Key FinancialsYear ending 31/12/2025
Net Worth
£975
Balance sheet strength
Cash
—
Cash in the bank
Net Current Assets
-£5.9M
Working capital
Current Assets
—
Current Liabilities
£5.9M
Profit After Tax
-£7.8M
EstimatesDerived
| Year | Current Ratio | Implied Profit |
|---|---|---|
| 2024 | 0.00 | — |
| 2023 | 0.03 | — |
| 2022 | 0.04 | -£95k |
| 2021 | 3.30 | — |
| 2020 | 5.97 | — |
| 2019 | 11.17 | — |
Derived from filed accounts. Not audited figures.